Special Issue "Novel Therapeutic Approaches for Pulmonary Hypertension"
Deadline for manuscript submissions: 30 November 2023 | Viewed by 16805
Interests: pulmonary hypertension; pulmonary embolism; pulmonary arterial hypertension; chronic thromboembolic pulmonary hypertension; balloon pulmonary angioplasty; echocardiography
Over the past 25 years, tremendous progress has been made in the therapeutic possibilities for pulmonary hypertension. This statement applies to both pharmacological and surgical or percutaneous interventions. The goals and methods of therapy differ significantly depending on the etiology of pulmonary hypertension. In group I, according to current ESC/ERS Guidelines (pulmonary arterial hypertension, PAH), the introduction of epoprostenol and other drugs from the targeted therapy at the turn of the 20th and 21st centuries changed the "primary pulmonary hypertension" from a clearly fatal condition to more chronic disease. The following years brought numerous studies of new drugs and their combinations to obtain the optimal therapeutic effect. Interventional methods such as atrial septostomy, Pott's anastomosis, and pulmonary artery denervation are also utilized to reduce right ventricular failure. Lung transplantation remains the ultimate treatment for PAH, but the timing of listing for this procedure is still not clearly defined. Drugs that proved successful in treating PAH were tested in patients with post-capillary pulmonary hypertension (group II) and pulmonary hypertension associated with chronic pulmonary diseases (group III). The results of these studies are inconclusive and do not clearly indicate which patients benefit from PAH-like therapy. In contrast, many interventions that control the underlying heart failure or chronic pulmonary disease have beneficial effects on pulmonary artery pressure and the degree of right ventricular failure. Balloon pulmonary angioplasty and modern pharmacological treatment have been added to pulmonary endarterectomy, the recognized treatment option for chronic thromboembolic pulmonary hypertension. It gave an unprecedented possibility of treatment which is tailored to the individual subject. Research on novel therapeutic approaches is still underway and goes beyond the well-known canons of management.
In the present Special Issue, we want to gather a collection of original, interesting and innovative papers on new therapeutic options for pulmonary hypertension. We invite authors of papers in the field of clinical medicine in the adult and pediatric populations and basic science researchers who work on experimental studies facilitating new therapeutic options. Let this Special Issue be a forum for the exchange of fresh ideas and innovative concepts!
Prof. Dr. Marcin Kurzyna
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Pulmonary hypertension
- Pulmonary arterial hypertension
- Chronic thromboembolic pulmonary hypertension
- Congenital heart disease
- Congestive heart failure
- Balloon pulmonary angioplasty
- Atrial septostomy
- Pulmonary artery denervation
- Lung transplantation